Forty Seven Completes $75 Million Series A Financing Round and Licenses Technology from Stanford University

On February 24, 2016, clinical-stage immuno-oncology company Forty Seven announced that it has completed the first half of a committed $75 million Series A round of financing and has licensed the rights to multiple immuno-oncology programs from Stanford University. Wilson Sonsini Goodrich & Rosati represented Forty Seven in intellectual property matters and matters related to the licensing agreement.

According to Forty Seven's press release, the license includes the rights to more than 100 issued or pending U.S. or foreign patents that cover the antibody Hu5F9-G4 and several other novel immune checkpoint inhibitors and cancer-specific antibodies.

The WSGR team that represented Forty Seven in the transaction included Vern Norviel, Ian Edvalson, James Langston, and David Harburger.

For more information, please see Forty Seven's press release.